Liver Diseases  >>  Avastin (bevacizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

17 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avastin (bevacizumab) / Roche
NCT00142467: Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

Completed
2
33
US
Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Bevacizumab, Avastin
Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Genentech, Inc., Sanofi-Synthelabo, Eli Lilly and Company
Hepatocellular Carcinoma
08/06
06/11
NCT00106054: Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases

Terminated
2
2
US
Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.
Pfizer
Colorectal Neoplasms, Liver Neoplasms
09/06
09/06
NCT00043004: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer

Terminated
2
119
Europe, RoW
bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiofrequency ablation
European Organisation for Research and Treatment of Cancer - EORTC, Arbeitsgruppe Lebermetastasen und Tumoren, Institute of Cancer Research, United Kingdom
Colorectal Cancer, Metastatic Cancer
06/07
 
NCT02013830: A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

Completed
2
45
RoW
bevacizumab [Avastin], capecitabine [Xeloda]
Hoffmann-La Roche
Liver Cancer
03/08
03/08
NCT00365391: Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer

Checkmark Data
Jul 2011 - Sep 2011: Data
Checkmark P2 data
Sep 2011 - Sep 2011: P2 data
Completed
2
27
US
bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774
National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
08/08
06/10
NCT00508872: Folfox-B Study for Patients With Colorectal Liver Metastases

Terminated
2
2
US
5-Fluorouracil, 5-FU, Adrucil, Efudex, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Leucovorin, Citrovorum, Wellcovorin, Oxaliplatin, Eloxatin
M.D. Anderson Cancer Center, Sanofi
Colorectal Liver Metastases
06/09
06/09
NCT00280007 / 2004-004963-32: Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma

Terminated
2
32
Europe
bevacizumab, -avastin
Medical University of Vienna
Hepatocellular Carcinoma
12/09
12/10
NCT00287222: Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

Completed
2
21
US
Bevacizumab, Avastin, Erlotinib, Tarceva
University of Arkansas, Genentech, Inc.
Hepatocellular Carcinoma
09/10
09/10
NCT00605722: A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Completed
2
51
RoW
bevacizumab (Avastin), erlotinib (Tarceva)
Hoffmann-La Roche
Liver Cancer
09/10
09/10
NCT00775073 / 2007-005422-76: Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001

Checkmark P2 data-ILCA
Sep 2012 - Sep 2012: P2 data-ILCA
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Checkmark Data-DDW
More
Completed
2
33
Europe
Everolimus, Bevacizumab, RAD001, Avastin
Gerhard Treiber, Crolll Gmbh, Estimate, GmbH, Janssen Diagnostics, LLC
Hepatocellular Carcinoma
01/11
04/12
NCT00576199: A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer

Completed
2
30
RoW
Bevacizumab, Avastin, Transarterial chemoembolisation (TACE)
Hoffmann-La Roche
Liver Cancer
05/11
05/11
NCT00242502: Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery

Checkmark P2 data
Feb 2012 - Feb 2012: P2 data
Completed
2
62
US
Bevacizumab (Avastin), Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Erlotinib, Erlotinib Hydrochloride, OSI-774, Tarceva
M.D. Anderson Cancer Center, Genentech, Inc.
Hepatocellular Carcinoma, Liver Cancer
10/11
10/11
PERIMAX, NCT01540435 / 2010-023575-25: Perioperative Treatment of Resectable Liver Metastases

Withdrawn
2
0
Europe
Bevacizumab, VEGF antibody
University of Regensburg, University of Halle Medical Faculty
Colon Cancer Liver Metastasis
05/13
05/13
NCT01320683: Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer

Terminated
2
1
US
oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, laboratory biomarker analysis, pharmacological study, pharmacological studies, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E
City of Hope Medical Center, National Cancer Institute (NCI)
Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
12/14
12/14
NCT00881751: Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

Checkmark ASCO-GI 2015
Jan 2015 - Jan 2015: ASCO-GI 2015
Completed
2
95
US
bevacizumab, erlotinib hydrochloride, sorafenib tosylate
Medical University of South Carolina
Liver Cancer
05/16
02/17
BOS2, NCT01508000 / 2010-019238-29: Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases

Checkmark For wild-type RAS mutant 1st-line mCRC
Jun 2013 - Jun 2013: For wild-type RAS mutant 1st-line mCRC
Terminated
2
44
Europe
FOLFOX6, Chemotherapy, Bevacizumab, Avastin, Panitumumab, Vectibix, Surgery
European Organisation for Research and Treatment of Cancer - EORTC, Amgen, Roche Pharma AG
Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer
09/16
09/16
NCT01010126: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Checkmark P2 data
More
Completed
2
252
Canada, US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
03/17
03/17

Download Options